聖湘生物(688289.SH):與科華生物擬在化學發光免疫細分領域展開合作 設合資公司
格隆匯11月8日丨聖湘生物(688289.SH)公佈,為進一步完善公司業務佈局、提升綜合競爭能力,公司與科華生物擬在化學發光免疫細分領域展開合作,充分實現優勢互補、互利共贏。雙方簽訂了《投資框架意向書》,由公司與科華生物合計出資5000萬元,投資設立合資公司“湖南聖科生物技術有限公司(Sansure Immunotech)”(擬用名,最終以市場監督管理局核准註冊為準),合資公司以科華生物控股目標公司的形式設立,合資公司財務報表納入科華生物合併報表範圍。合資公司股權比例為:科華生物佔比50%,聖湘生物佔比50%。
作為免疫診斷領域中的新技術,化學發光免疫分析結合了化學發光的高靈敏度和免疫分析的高特異性,在臨牀檢驗、藥物分析、環境監測等領域得到了廣泛應用。隨着集採、DRGs 帶來的檢測價格下降和居民高端檢測需求提升,化學發光診斷市場的需求將呈現明顯上升趨勢。
在產品線方面,通過合作成立合資公司,能依託科華生物在化學發光免疫領域較強的研發基礎和儀器平台優勢,結合雙方的研發能力,豐富化學發光產品線,提升產品核心競爭力,為拓展市場持續提供動力。
在產品註冊方面,合資公司可藉助湖南有關政策優勢,通過“註冊轉移”+“新品研發”相結合的方式快速完善產品註冊,大大縮短產品註冊週期,加快完成產品的成果轉換,並投入市場。同時,藉助公司國際化的註冊團隊,在歐盟、拉美等區域逐步完成產品註冊,拓展國際市場,有效提高全球市場佔有率。
在市場渠道方面,合資公司可藉助科華生物、聖湘生物豐富的上下游業務渠道、成熟的渠道體系和渠道管理模式,擴大公司產品在國際市場的覆蓋,強化國際市場的深耕與佈局,為未來開拓並站穩國際市場打下基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.